OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Icaritin inhibits PD‐L1 expression by Targeting Protein IκB Kinase α
Dongliang Mo, Hai Zhu, Jun Wang, et al.
European Journal of Immunology (2020) Vol. 51, Iss. 4, pp. 978-988
Open Access | Times Cited: 47
Dongliang Mo, Hai Zhu, Jun Wang, et al.
European Journal of Immunology (2020) Vol. 51, Iss. 4, pp. 978-988
Open Access | Times Cited: 47
Showing 1-25 of 47 citing articles:
Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets
Xiangyuan Luo, Kongming Wu, Xingxing He
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 147
Xiangyuan Luo, Kongming Wu, Xingxing He
Journal of Experimental & Clinical Cancer Research (2021) Vol. 40, Iss. 1
Open Access | Times Cited: 147
MYC Oncogene: A Druggable Target for Treating Cancers with Natural Products
Ka Iong Chan, Siyuan Zhang, Guodong Li, et al.
Aging and Disease (2024) Vol. 15, Iss. 2, pp. 640-640
Open Access | Times Cited: 17
Ka Iong Chan, Siyuan Zhang, Guodong Li, et al.
Aging and Disease (2024) Vol. 15, Iss. 2, pp. 640-640
Open Access | Times Cited: 17
Icaritin with autophagy/mitophagy inhibitors synergistically enhances anticancer efficacy and apoptotic effects through PINK1/Parkin-mediated mitophagy in hepatocellular carcinoma
Piao Luo, Yehai An, Jingqian He, et al.
Cancer Letters (2024) Vol. 587, pp. 216621-216621
Closed Access | Times Cited: 16
Piao Luo, Yehai An, Jingqian He, et al.
Cancer Letters (2024) Vol. 587, pp. 216621-216621
Closed Access | Times Cited: 16
Transplant oncology and anti-cancer immunosuppressants
Dejun Kong, Jinliang Duan, Shiyi Chen, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Dejun Kong, Jinliang Duan, Shiyi Chen, et al.
Frontiers in Immunology (2025) Vol. 15
Open Access | Times Cited: 1
Icariin and its metabolites as potential protective phytochemicals against cardiovascular disease: From effects to molecular mechanisms
Yufei Zeng, Yilin Xiong, Tao Yang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112642-112642
Open Access | Times Cited: 53
Yufei Zeng, Yilin Xiong, Tao Yang, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 147, pp. 112642-112642
Open Access | Times Cited: 53
Small-molecule-based targeted therapy in liver cancer
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
Ming Yue, Yanqiu Gong, Xuewen Fu, et al.
Molecular Therapy (2024) Vol. 32, Iss. 10, pp. 3260-3287
Closed Access | Times Cited: 9
Phytochemicals in Cancer Immune Checkpoint Inhibitor Therapy
Juwon Lee, Youngjin Han, Wenyu Wang, et al.
Biomolecules (2021) Vol. 11, Iss. 8, pp. 1107-1107
Open Access | Times Cited: 45
Juwon Lee, Youngjin Han, Wenyu Wang, et al.
Biomolecules (2021) Vol. 11, Iss. 8, pp. 1107-1107
Open Access | Times Cited: 45
Chinese Herbal Medicine for Primary Liver Cancer Therapy: Perspectives and Challenges
Kexin Li, Kunmin Xiao, Shijie Zhu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 35
Kexin Li, Kunmin Xiao, Shijie Zhu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 35
Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy
Kunjing Liu, Qi Sun, Qi Liu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113618-113618
Open Access | Times Cited: 31
Kunjing Liu, Qi Sun, Qi Liu, et al.
Biomedicine & Pharmacotherapy (2022) Vol. 154, pp. 113618-113618
Open Access | Times Cited: 31
Icaritin: A phytomolecule with enormous pharmacological values
Nguyen Thi Huong, Ninh The Son
Phytochemistry (2023) Vol. 213, pp. 113772-113772
Closed Access | Times Cited: 17
Nguyen Thi Huong, Ninh The Son
Phytochemistry (2023) Vol. 213, pp. 113772-113772
Closed Access | Times Cited: 17
Escherichia coli‐Induced cGLIS3‐Mediated Stress Granules Activate the NF‐κB Pathway to Promote Intrahepatic Cholangiocarcinoma Progression
Feng‐Ping Kang, Zhi‐Wen Chen, Cheng‐Yu Liao, et al.
Advanced Science (2024) Vol. 11, Iss. 16
Open Access | Times Cited: 6
Feng‐Ping Kang, Zhi‐Wen Chen, Cheng‐Yu Liao, et al.
Advanced Science (2024) Vol. 11, Iss. 16
Open Access | Times Cited: 6
Traditional Chinese medicine for the treatment of cancers of hepatobiliary system: from clinical evidence to drug discovery
Junyu Wu, Guping Tang, Chien‐shan Cheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Junyu Wu, Guping Tang, Chien‐shan Cheng, et al.
Molecular Cancer (2024) Vol. 23, Iss. 1
Open Access | Times Cited: 5
Icariin mediates autophagy and apoptosis of hepatocellular carcinoma cells induced by the β-catenin signaling pathway through lncRNA LOXL1-AS1
Sicheng Gao, Wanyi Zhang, Jinhua Dai, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Sicheng Gao, Wanyi Zhang, Jinhua Dai, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2025)
Open Access
Advances in Pharmacological Research on Icaritin: A Comprehensive Review
Ran Guo, Zhiping Yan, Rui Wang, et al.
The American Journal of Chinese Medicine (2025), pp. 1-25
Closed Access
Ran Guo, Zhiping Yan, Rui Wang, et al.
The American Journal of Chinese Medicine (2025), pp. 1-25
Closed Access
The Potential Role of PD-1/PD-L1 Small Molecule Inhibitors in Colorectal Cancer with Different Mechanisms of Action
Suhaibee Kuno, Nattaporn Pakpian, Chatchai Muanprasat
European Journal of Pharmacology (2025), pp. 177351-177351
Closed Access
Suhaibee Kuno, Nattaporn Pakpian, Chatchai Muanprasat
European Journal of Pharmacology (2025), pp. 177351-177351
Closed Access
Antineoplastic effects of icaritin: molecular mechanisms and applications
Piao Luo, Liyang Zhang, Guangqing Cheng, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 2
Open Access
Piao Luo, Liyang Zhang, Guangqing Cheng, et al.
Acta Materia Medica (2025) Vol. 4, Iss. 2
Open Access
A bibliometric and visualization analysis of the role of traditional Chinese medicine in cancer immunotherapy
Yixiao Lian, Jie Sun, Lin Yang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Yixiao Lian, Jie Sun, Lin Yang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Flavonoids in the Treatment of Non-small Cell Lung Cancer via Immunomodulation: Progress to Date
Mengdi Liang, Yang Huang, Shengfeng Huang, et al.
Molecular Diagnosis & Therapy (2025)
Closed Access
Mengdi Liang, Yang Huang, Shengfeng Huang, et al.
Molecular Diagnosis & Therapy (2025)
Closed Access
First‐Line Treatment of Icaritin and Thalidomide in a Patient With Hepatocellular Carcinoma With PR : A Case Report
Zhi‐Cheng Jin, Fei Zhou, Zhuo Wang, et al.
Cancer Reports (2025) Vol. 8, Iss. 3
Open Access
Zhi‐Cheng Jin, Fei Zhou, Zhuo Wang, et al.
Cancer Reports (2025) Vol. 8, Iss. 3
Open Access
New insights into the anticancer therapeutic potential of icaritin and its synthetic derivatives
Octavio D. Reyes‐Hernández, Gabriela Figueroa‐González, Laura Itzel Quintas‐Granados, et al.
Drug Development Research (2024) Vol. 85, Iss. 2
Closed Access | Times Cited: 4
Octavio D. Reyes‐Hernández, Gabriela Figueroa‐González, Laura Itzel Quintas‐Granados, et al.
Drug Development Research (2024) Vol. 85, Iss. 2
Closed Access | Times Cited: 4
A Mini-Review of Flavone Isomers Apigenin and Genistein in Prostate Cancer Treatment
Xiaozhen Ji, Kai Liu, Qingyue Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
Xiaozhen Ji, Kai Liu, Qingyue Li, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 20
The current status and future of PD-L1 in liver cancer
Liyuan Hao, Shenghao Li, Jiali Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Liyuan Hao, Shenghao Li, Jiali Deng, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Nature’s Arsenal: Harnessing the Capacity of Phytochemicals to Enhance Immune Checkpoint Inhibitor Therapy of Cancers: An Especial Attention to Brain Malignancies
Amir R. Afshari, Mehdi Sanati, Seyed Sajad Ahmadi, et al.
Cancer Letters (2024) Vol. 593, pp. 216955-216955
Closed Access | Times Cited: 3
Amir R. Afshari, Mehdi Sanati, Seyed Sajad Ahmadi, et al.
Cancer Letters (2024) Vol. 593, pp. 216955-216955
Closed Access | Times Cited: 3
The NF-κB Pharmacopeia: Novel Strategies to Subdue an Intractable Target
Daniela Verzella, Jessica Cornice, Paola Arboretto, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2233-2233
Open Access | Times Cited: 17
Daniela Verzella, Jessica Cornice, Paola Arboretto, et al.
Biomedicines (2022) Vol. 10, Iss. 9, pp. 2233-2233
Open Access | Times Cited: 17
Epimedokoreanin B inhibits the growth of lung cancer cells through endoplasmic reticulum stress-mediated paraptosis accompanied by autophagosome accumulation
Hao Zheng, Qingying Liu, Shuqi Wang, et al.
Chemico-Biological Interactions (2022) Vol. 366, pp. 110125-110125
Closed Access | Times Cited: 14
Hao Zheng, Qingying Liu, Shuqi Wang, et al.
Chemico-Biological Interactions (2022) Vol. 366, pp. 110125-110125
Closed Access | Times Cited: 14
